Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in iHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year-over-year in life sciences and food safety [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIT solution sales increased by 21% year-to-date, contributing to the overall revenue growth [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide positions the company to serve not only life sciences and healthcare but also agriculture, food processing, and environmental biosafety [7][23] - The active pipeline surpassed $15 million, encompassing both domestic and international customers across various industries [6] Company Strategy and Development Direction - The company aims to enhance customer engagement and expand its recurring revenue streams through personalized outreach and targeted marketing campaigns [8] - Focus on biosecurity advancements and scaling automation integrations for high-efficacy environments is prioritized for 2026 [8][9] - The company is investing in innovation and customer success to capture opportunities in clean tech and biosecurity [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's recovery and reaffirmed the soundness of its strategy, with steady improvement expected financially, operationally, and strategically [25][26] - The company is well-positioned for a successful fourth quarter with momentum carrying into 2026, supported by a recent equity purchase agreement to access capital [26][27] Other Important Information - The company celebrated a significant addition to its customer roster with Bausch + Lomb, which adopted mobile handheld surface units and committed to BIT Solution orders for 2026 [19][20] - The company is actively pursuing the cannabis market and has opened doors to promising new partnership discussions [22] Q&A Session Summary Question: What are your sales and marketing efforts towards the FDA approval for hydrogen peroxide usage? - Management indicated that the food industry could be a key marketing vertical, and they are excited about the approval as it positions their technology favorably [29] Question: Should we expect operating expenses and gross margins to continue improving? - Management expects operating expenses to increase but remain positive in relation to revenue, with gross margins expected to hold steady [30][31] Question: What kind of sales effort is in place for international markets like Morocco? - The company has distributors in various countries and is working with global partners to increase demand for SteraMist [34] Question: Do you have visibility on solution sales in the coming quarters? - Management noted that while there was a decrease in solution sales growth in Q3, they expect a rebound by the end of the fourth quarter [35] Question: Any updates on servicing military and defense markets? - Management mentioned ongoing studies with a key site looking to replace formaldehyde, with expectations for significant developments in 2026 [42] Question: Any progress in the use of SteraMist for replacing ethylene oxide in medical sterilization? - Management confirmed ongoing discussions and prioritization of partnerships in device manufacturing for this purpose [51]

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in IHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year over year in the life sciences and food safety areas [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIP solution sales increased by 21% year to date, indicating a positive trend in this segment [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide as a safe disinfectant opens new markets, particularly in food safety, agriculture, and environmental biosafety [7][23] - The company is seeing strong interest from emerging sectors, with an active pipeline surpassing $15 million [6] Company Strategy and Development Direction - The company aims to grow sales of mobile capital equipment, IHP corporate service, and custom integration platforms alongside its core BIP solution business model [5] - There is a focus on biosecurity advancements and scaling automation integrations for high-efficacy environments, addressing global challenges [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's recovery and strategic execution, highlighting steady improvement financially, operationally, and strategically [25] - The company is well-positioned for a successful fourth quarter with momentum carrying into 2026, supported by a recent equity purchase agreement to access capital [26] Other Important Information - The company has been recognized as the Disinfection and Decontamination Products Company of the Year 2025, validating its solutions and positioning [7] - The company is expanding its training programs and customer engagement strategies to enhance market penetration [8] Q&A Session Summary Question: What are the sales and marketing efforts towards the FDA approval for hydrogen peroxide? - Management indicated that the food industry could be a key marketing vertical, and they are excited about the approval as it positions their technology favorably [30] Question: Should we expect operating expenses and gross margins to continue improving? - Management expects operating expenses to increase but remain positive in relation to revenue, with gross margins holding steady [31][32] Question: What kind of sales effort is in place for international markets like Morocco? - The company has distributors in various countries focused on increasing demand for SteraMist [36] Question: Do you have visibility on solution sales in the coming quarters? - Management noted that while they had a 40% increase in solution sales earlier in the year, they expect recurring sales to rise again by the end of Q4 [37] Question: Any updates on servicing military and defense markets? - Management mentioned ongoing studies with a key site looking to replace formaldehyde, expecting significant developments in 2026 [43] Question: Progress on CAR T-cell disinfection business? - No updates were provided on this front [45] Question: Expectations on the rollout by major service provider companies in healthcare mold remediation? - Management expressed optimism about rapid rollouts due to strong initial assessments and training support [46] Question: Plans to penetrate the disinfection market for data centers? - Management acknowledged the interest in data centers and the need for disinfection, indicating plans to expand the sales team for this vertical [49] Question: How is the company increasing awareness for the food industry post-FDA ruling? - The company is focusing on social media and reaching out to existing contacts in the food safety sector [51] Question: Any progress in using SteraMist for replacing ethylene oxide in medical sterilization? - Management confirmed ongoing discussions and prioritization of partnerships in this area [54]

Core Insights - XWELL, Inc. reported third-quarter revenue of approximately $7.3 million for the period ending September 30, 2025, with significant improvements in cost management and operational efficiency [6][15] - The company is expanding its wellness services beyond airport locations, with new centers opening in Florida and New York City, enhancing accessibility for consumers [3][7][14] - XWELL has streamlined its corporate cost structure, reducing annualized staffing costs by approximately $2.4 million, and integrated its HyperPointe™ business to optimize resources [4][5] Recent Operating Highlights - The CEO emphasized progress in diversifying access points and enhancing brand relevance, particularly through partnerships like the expanded collaboration with Priority Pass [3] - New off-airport wellness centers have been opened, including locations in Penn Station, New York, and various Florida markets, aimed at serving local consumers [3][6][7] Financial Overview - Revenue breakdown for Q3 2025: approximately $5.1 million from XpresSpa, $1.7 million from XpresCheck, and $0.5 million from Naples Wax Center [15] - Cost of sales decreased by about 8% compared to the same quarter in 2024, while general and administrative expenses fell by approximately 32% [6][15] - The operating loss for the quarter was approximately $0.8 million, a significant reduction from the $4.8 million loss in the prior year [15] Strategic Initiatives - XWELL's partnership with Priority Pass has expanded to key international airports in the Middle East and Europe, enhancing traveler access to wellness offerings [6][7] - The company is leveraging its biosecurity program, XpresCheck, to capture growth opportunities in travel and mass-gathering settings, including major global events [8][9][10] Liquidity and Financial Condition - As of September 30, 2025, XWELL had approximately $4.0 million in cash and cash equivalents, with total current assets of about $10.8 million and no long-term debt [11]

Core Insights - TOMI Environmental Solutions, Inc. reported a significant sequential revenue increase of 95% in Q3 2025, driven by higher equipment purchases and strong recurring sales of its BIT™ Solution [5][10] - The company is strategically positioned for long-term growth, with ongoing investments in R&D and expanding international market penetration [10][11] Financial Performance - Revenues for Q3 2025 were $2.0 million, a 95% increase from Q2 2025, but a decrease from $2.54 million in Q3 2024 [5][25] - Gross profit margin remained stable at 61% for Q3 2025, indicating operational efficiency [5][25] - Operating loss for Q3 2025 was $(321,000), compared to an operating income of $149,000 in Q3 2024 [5][25] - Net loss for Q3 2025 was $(450,000) or $(0.02) per share, compared to a net income of $59,000 or $0.00 per share in Q3 2024 [5][25] Business Highlights - The company achieved a 21% year-over-year increase in SteraMist solution sales for the nine months ended September 30, 2025 [5] - International revenue accounted for nearly 36% of Q3 revenue, up from 20% in Q2 2025, reflecting successful global market penetration [5] - The sales order backlog grew to $0.9 million at quarter-end and expanded to $1.3 million by October 31, with approximately $3 million in pending contracts expected to close before year-end [5] Strategic Initiatives - The company is focusing on expanding its product applications across various sectors, including life sciences, healthcare, food safety, and commercial markets [5][10] - A new equity line of credit allows the company to sell up to $20 million in common stock over a 24-month period, enhancing financial flexibility [8][9] - The FDA's expanded approval for hydrogen peroxide use is expected to broaden the application of SteraMist iHP technology, targeting food, agriculture, and environmental biosecurity markets [10][12] Liquidity and Capital Access - As of September 30, 2025, the company had working capital of $2.5 million, with cash used in operations improving by approximately $876,000 compared to the same period in 2024 [7] - The company completed a $535,000 convertible note financing to support growth initiatives [7] Executive Commentary - The CEO highlighted the strong revenue growth and new customer partnerships as evidence of the effectiveness of the company's strategy and execution [10] - The company is optimistic about maintaining momentum into Q4 2025 and throughout 2026, supported by a growing customer base and expanding sales [11][12]

Company Overview - Ginkgo Bioworks is focused on building a leading platform for cell programming and biosecurity [1] - The company offers customizable R&D packages, including protein engineering and nucleic acid design, to accelerate innovation in therapeutics, diagnostics, and manufacturing [3] - Ginkgo Automation provides modular laboratory automation solutions to enhance scientific productivity [3] - Ginkgo Biosecurity is developing next-generation infrastructure and technologies to address biological threats [3] Upcoming Events - Ginkgo Bioworks will host a presentation and Q&A session on August 7, 2025, to review its business performance for Q2 2025 [1] - The session will begin at 5:30 p.m. ET and will be available via webcast on the company's investor relations website [2] - Questions can be submitted in advance through social media or email [2]

US-Australia Trade Relations - A meeting regarding trade between the US and Australia is unlikely to result in significant tariff changes [1] - The US has concerns regarding Australia's biosecurity measures, particularly related to beef imports [4] - Australia has maintained a trade surplus with the US since 1952 [4] - While Australia only exports about 4% of its total goods to the US, the US is the biggest investor in Australia and the biggest destination for Australian capital, with approximately 14 trillion in each direction [9][10] Beef Trade Dispute - The US seeks assurance that beef exported to Australia is born and bred in the US, not from cattle crossing the borders from Mexico and Canada [6] - Australia is standing firm on its biosecurity measures regarding beef imports [7] - The US President is concerned that Australia hasn't allowed one American Big Mac into the country [6] Geopolitical and Economic Concerns - Actions in the Middle East are currently considered more important than trade matters with Australia [3] - The slowdown of the Chinese economy is a significant concern for Australian companies [8] - China's potential limitations on exports of critical minerals needed in batteries could impact Australian companies [9] Shipbuilding and AUKUS - The US is prioritizing increasing its shipbuilding capacity [12] - An Australian company, Austal, operating in Alabama, has built approximately a third of the ships in the US Navy [13] - Australia has made an 800 million AUD down payment on the 3 billion AUD investment in the subs uplift [15] - There is no expectation that AUKUS will be cancelled, as it is in America's strategic and economic interests [15]

Core Insights - Ginkgo Bioworks has made significant progress in its restructuring efforts, targeting $250 million in cost savings by Q3 2025 [1][3][7] - The company reported a total revenue of $48 million for Q1 2025, a 27% increase from $38 million in the same period last year, primarily due to a $7 million non-cash revenue release [6][22] - Ginkgo's Solutions business is becoming a trusted R&D service provider for the US Government and biopharma industry, while its Tools business is gaining traction in AI-related opportunities [3][7] Financial Performance - Q1 2025 total revenue was $48 million, with $31 million from Cell Engineering (up 10% year-over-year) and $10 million from Biosecurity (flat year-over-year) [6][22] - The company reported a GAAP net loss of $91 million for Q1 2025, an improvement from a net loss of $166 million in the prior year [6][22] - Adjusted EBITDA for Q1 2025 was $(47) million, an improvement from $(117) million in the prior year, driven by increased revenue and reduced operating expenses [6][22] Strategic Positioning - Ginkgo is well-positioned in the biotechnology sector, with 28 US Government projects and a contracted backlog of approximately $180 million [7] - The company is focusing on biosecurity and R&D services, which are deemed critical by national policy reports [7] - Ginkgo's Datapoints and Automation offerings are generating new deals, including a recent agreement with Aura Genetics [7] Guidance and Outlook - Ginkgo has updated its 2025 guidance to reflect total revenue expectations of $160-$180 million, with Cell Engineering revenue projected at $110-$130 million and Biosecurity revenue at least $50 million [5][13] - The company aims to achieve Adjusted EBITDA breakeven by the end of 2026 [7]

Core Insights - TOMI Environmental Solutions, Inc. has successfully deployed its SteraMist iHP technology at NASA Johnson Space Center, marking its entry into the aerospace sector [1][2] - The technology is being utilized in a biosafety cabinet for handling samples from the Mars Perseverance Rover mission, demonstrating its application in space exploration [2][3] - This deployment is part of TOMI's strategic SteraMistX campaign, which aims to enhance biosecurity standards in aerospace and military fields [4] Company Overview - TOMI Environmental Solutions, Inc. is a global leader in disinfection and decontamination solutions, utilizing technology developed through DARPA [1][5] - The company's primary product, the Binary Ionization Technology (BIT) platform, employs a low percentage of hydrogen peroxide as its active ingredient, providing superior disinfection capabilities [5] - TOMI's products are designed for a wide range of environments, including hospitals, biosafety labs, pharmaceutical facilities, and more [5]